The chemotherapy drug cisplatin kills cancer cells by damaging their DNA. It has been used for treating a variety of cancer types for almost four decades. Although the drug is generally effective, it has strong adverse side effects, and some cancers exhibit or, after initial favorable response, develop drug resistance. The mechanism of drug resistance is multifactorial and involves the ability of cancer cells to repair the cisplatin-induced DNA damages. We have developed methods to map the sites of cisplatin damage and its repair for the entire human genome at single-nucleotide resolution. These methods can be used to study cancer sensitivity and resistance to the drugs, and to identify new strategies for efficient combination therapies
Cisplatin is a DNA-targeting chemotherapeutic, yet its damaged gene loci are largely unexplored. We ...
Nucleotide excision repair removes DNA damage caused by carcinogens, such as UV and anticancer drugs...
Studies were undertaken to investigate acquired resistance to cisplatin in human ovarian cancer cell...
The chemotherapy drug cisplatin kills cancer cells by damaging their DNA. It has been used for treat...
The platinum-based drug cisplatin is a widely used first-line therapy for several cancers. Cisplatin...
The platinum-based drug cisplatin is a widely used first-line therapy for several cancers. Cisplatin...
The platinum-based drug cisplatin is a widely used first-line therapy for several cancers. Cisplatin...
The main goal of chemotherapeutic drugs is to induce massive cell death in tumors. Cisplatin is an a...
The main goal of chemotherapeutic drugs is to induce massive cell death in tumors. Cisplatin is an a...
Cisplatin, one of the most widely used anticancer drugs, crosslinks DNA and ultimately induces cell ...
Platinum-based chemotherapies, such as cisplatin, play a large role in cancer treatment. The develop...
The DNA-damaging compound, cisplatin (cis-diamminedichloridoplatinum(II)), is a highly successful an...
The anticancer drug cisplatin is a small inorganic molecule that forms several types of covalent add...
Lung cancer is the most common cause of death from cancer worldwide per year. Platinum-based combina...
Cisplatin is a DNA-targeting chemotherapeutic, yet its damaged gene loci are largely unexplored. We ...
Cisplatin is a DNA-targeting chemotherapeutic, yet its damaged gene loci are largely unexplored. We ...
Nucleotide excision repair removes DNA damage caused by carcinogens, such as UV and anticancer drugs...
Studies were undertaken to investigate acquired resistance to cisplatin in human ovarian cancer cell...
The chemotherapy drug cisplatin kills cancer cells by damaging their DNA. It has been used for treat...
The platinum-based drug cisplatin is a widely used first-line therapy for several cancers. Cisplatin...
The platinum-based drug cisplatin is a widely used first-line therapy for several cancers. Cisplatin...
The platinum-based drug cisplatin is a widely used first-line therapy for several cancers. Cisplatin...
The main goal of chemotherapeutic drugs is to induce massive cell death in tumors. Cisplatin is an a...
The main goal of chemotherapeutic drugs is to induce massive cell death in tumors. Cisplatin is an a...
Cisplatin, one of the most widely used anticancer drugs, crosslinks DNA and ultimately induces cell ...
Platinum-based chemotherapies, such as cisplatin, play a large role in cancer treatment. The develop...
The DNA-damaging compound, cisplatin (cis-diamminedichloridoplatinum(II)), is a highly successful an...
The anticancer drug cisplatin is a small inorganic molecule that forms several types of covalent add...
Lung cancer is the most common cause of death from cancer worldwide per year. Platinum-based combina...
Cisplatin is a DNA-targeting chemotherapeutic, yet its damaged gene loci are largely unexplored. We ...
Cisplatin is a DNA-targeting chemotherapeutic, yet its damaged gene loci are largely unexplored. We ...
Nucleotide excision repair removes DNA damage caused by carcinogens, such as UV and anticancer drugs...
Studies were undertaken to investigate acquired resistance to cisplatin in human ovarian cancer cell...